Literature DB >> 11737868

Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report.

A A Cagatay1, S S Oncü, S S Calangu, T T Yildirmak, H H Ozsüt, H H Eraksoy.   

Abstract

BACKGROUND: Mucormycosis (or zygomycosis) is the term for infection caused by fungi of the order Mucorales. Mucoraceae may produce severe disease in susceptible individuals, notably patients with diabetes and leukemia. Rhinocerebral mucormycosis most commonly manifests itself in the setting of poorly controlled diabetes, especially with ketoacidosis. CASE
PRESENTATION: A 31-year-old diabetic man presented to the outpatient clinic with the following signs and symptoms: headache, periorbital pain, swelling and loss of vision in the right eye. On physical examination his right eye was red and swollen. There was periorbital cellulitis and the conjunctiva was edematous. KOH preparation of purulent discharge showed broad, ribbonlike, aseptate hyphae when examined under a fluorescence microscope. Cranial MRI showed involvement of the right orbit, thrombosis in cavernous sinus and infiltrates at ethmoid and maxillary sinuses. Mucormycosis was diagnosed based on these findings. Amphotericin B (AmBisome(R); 2 mg/kg.d) was initiated after the test doses. Right orbitectomy and right partial maxillectomy were performed; the lesions in ethmoid and maxillary sinuses were removed. The duration of the liposomal amphotericin B therapy was approximately 6 months and the total dose of liposomal amphotericin B used was 32 grams. Liposomal amphotericin B therapy was stopped six months later and oral fluconazole was started.
CONCLUSIONS: Although a total surgical debridement of the lesions could not be performed, it is remarkable that regression of the disease could be achieved with medical therapy alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737868      PMCID: PMC60655          DOI: 10.1186/1471-2334-1-22

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  15 in total

Review 1.  Amphotericin B: delivery systems.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery.

Authors:  M Ericsson; M Anniko; H Gustafsson; C A Hjalt; R Stenling; A Tärnvik
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

3.  Another case report of rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery.

Authors:  K K Lim; M J Potts; D W Warnock; N B Ibrahim; E M Brown; C J Burns-Cox
Journal:  Clin Infect Dis       Date:  1994-04       Impact factor: 9.079

Review 4.  Mucormycosis.

Authors:  A M Sugar
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

Review 5.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

6.  Fluconazole therapy for pulmonary mucormycosis complicating acute leukemia.

Authors:  H Funada; Y Miyake; K Kanamori; K Okafuji; T Machi; T Matsuda
Journal:  Jpn J Med       Date:  1989 Mar-Apr

7.  Mucormycosis in a diabetic child and its treatment with fluconazole: a case report.

Authors:  D Selcen; G Seçmeer; S Aysun; G Kanra; M Onerci; A Gököz; Z Ecevit; M Ceyhan; Y Anlar
Journal:  Turk J Pediatr       Date:  1995 Apr-Jun       Impact factor: 0.552

Review 8.  New methods for delivery of antifungal agents.

Authors:  F Meunier
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

9.  Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases.

Authors:  N A Parfrey
Journal:  Medicine (Baltimore)       Date:  1986-03       Impact factor: 1.889

Review 10.  Zygomycosis.

Authors:  M G Rinaldi
Journal:  Infect Dis Clin North Am       Date:  1989-03       Impact factor: 5.982

View more
  10 in total

1.  In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Teresa Peláez; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 2.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

3.  Rapidly progressive rhino-orbito-cerebral mucormycosis in a patient with type 2 diabetes: A case report.

Authors:  Yan-Xia Chen; Yin-Xi He; Hong Zhou; Mian Wang; Sheng-Ou Su
Journal:  Exp Ther Med       Date:  2017-01-20       Impact factor: 2.447

4.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Rhino-oculo Cerebral Mucormycosis with Multiple Cranial Nerve Palsy in Diabetic Patient: Review of Six Cases.

Authors:  Kavita Sachdeva
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-05-14

6.  Rhino-orbital mucourmycosis in a non-immunocompromised patient.

Authors:  Asifur Rahman; Khaleda Akter; Shakhawat Hossain; Harun Ur Rashid
Journal:  BMJ Case Rep       Date:  2013-02-06

7.  Comparison of lipid amphotericin B preparations in treating murine zygomycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Mohamed I Husseiny; David A Stevens; Yue Fu; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

8.  A retrospective analysis of eleven cases of invasive rhino-orbito-cerebral mucormycosis presented with orbital apex syndrome initially.

Authors:  Nan Jiang; Guiqiu Zhao; Shanshan Yang; Jing Lin; Liting Hu; Chengye Che; Qian Wang; Qiang Xu
Journal:  BMC Ophthalmol       Date:  2016-01-12       Impact factor: 2.209

Review 9.  Mucormycosis: A deadly black fungus infection among COVID-19 patients in India.

Authors:  Naveen Kumar Choudhary; Amit K Jain; Rupesh Soni; Neha Gahlot
Journal:  Clin Epidemiol Glob Health       Date:  2021-11-01

10.  Intracranial hypertension: An unusual presentation of mucormycosis in a kidney transplant recipient.

Authors:  R Jha; D Gude; S Chennamsetty; H Kotari
Journal:  Indian J Nephrol       Date:  2013-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.